Literature DB >> 35247909

HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy.

Ke Liu1, Jun Huang2, Jiao Liu3, Changfeng Li4, Guido Kroemer5,6,7, Daolin Tang8, Rui Kang8.   

Abstract

SIGNIFICANCE: This study reveals an HSP90-centric, iron-modulated mechanism that confers immunosuppression, offering potential therapeutic targets for interfering with acquired resistance to the most prevalent anticancer immunotherapies. ©2022 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35247909     DOI： 10.1158/0008-5472.CAN-21-3917

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   13.312


  4 in total

1.  HSP90 as an emerging barrier to immune checkpoint blockade therapy.

Authors:  Daolin Tang; Rui Kang
Journal:  Oncoscience       Date:  2022-04-22

Review 2.  The V-ATPases in cancer and cell death.

Authors:  Fangquan Chen; Rui Kang; Jiao Liu; Daolin Tang
Journal:  Cancer Gene Ther       Date:  2022-05-03       Impact factor: 5.854

3.  Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade.

Authors:  Jiao Liu; Rui Kang; Guido Kroemer; Daolin Tang
Journal:  Oncoimmunology       Date:  2022-04-25       Impact factor: 7.723

Review 4.  Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy.

Authors:  Xiude Ren; Tao Li; Wei Zhang; Xuejun Yang
Journal:  Cells       Date:  2022-08-17       Impact factor: 7.666
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.